For Immediate Release
Chicago, IL – September 21, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (
PFE Quick Quote PFE - Free Report) , BioNTech ( BNTX Quick Quote BNTX - Free Report) , Moderna ( MRNA Quick Quote MRNA - Free Report) and Novavax ( NVAX Quick Quote NVAX - Free Report) . Here are highlights from Tuesday’s Analyst Blog: Vaccine Stocks Down After Biden Says Pandemic Is Over
The stocks of companies making COVID-19 vaccines and medicines declined on Monday after U.S. President Joe Biden said that the pandemic is over in the United States in an interview over the weekend on “60 Minutes” on CBS News.
BioNTech, Moderna and Novavax stocks declined 8.6%, 7.1% and 6.5%, respectively. Pfizer, BioNTech’s partner, declined around 1.3%.
The President said that though there was still a problem with COVID and a “lot of work” was going on for that, the pandemic was over. He said that the fact that no one is wearing masks suggests the pandemic is over in the country.
However, public health officials still consider the pandemic a health emergency and warn of a possible surge in infections in the fall and winter months. Thousands of people are being infected from the virus every day. Death rates from COVID are more than 400 per day, which though significantly down from a peak of more than 3,000 in late January 2021 and 2,600 in February 2022, are still quite high. Recently, the FDA granted emergency use authorization (EUA) to Pfizer/BioNTech and Moderna’s Omicron BA.4/BA.5-adapted bivalent vaccines for use as a single booster dose.
These “updated boosters” contain an mRNA encoding the spike protein present in the original vaccine as well as an mRNA encoding the spike protein that is common in the Omicron subvariants, BA.4 and BA.5, the most prevalent variants of concern in the United States as of now. Pfizer/BioNTech and Moderna developed the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA’s recommendation a couple of months back. The current vaccines weren’t very effective against the BA.4/BA.5 subvariants.
However, the pace of new hospitalizations has slowed down. Though the World Health Organization still considers COVID-19 a pandemic, its director general Tedros Adhanom Ghebreyesus said last week that the world is in a better position to end the pandemic. He went on to say that the end of the pandemic was in sight.
Stocks of Moderna, BioNTech and Novavax declined as their sales and profits will fall once the pandemic ends. This is because COVID-related vaccines and products were their only top-line drivers. The stocks of BioNTech and Moderna have risen almost 300% and 400%, respectively since March 2020 when the pandemic started.
In fact, pharma giant Pfizer’s stock too was hurt by Biden’s comment as its COVID-19 vaccine and antiviral, Paxlovid accounts for almost half its revenues. Pfizer and Moderna were expecting the “updated” boosters to be their key revenue drivers for the next few quarters. If the pandemic ends, the demand for COVID-19 vaccines and other medicines will decline, which will significantly hurt these companies’ sales and profits.
The companies will soon need to find new top-line drivers to fuel their long-term growth. Moderna, Pfizer and BioNTech have seen a major influx of cash from their vaccine/medicine sales. They can use the cash for more research and can successfully develop new products to make up for lost revenues from COVID products.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.